CN 105
Alternative Names: Ac-VSRRR-NH2; CN-105Latest Information Update: 27 Sep 2024
At a glance
- Originator CereNova; Duke University
- Developer AegisCN; Beijing Tian Tan Hospital; Duke University
- Class Anti-inflammatories; Antihaemorrhagics; Apolipoprotein therapeutics; Behavioural disorder therapies; Neuropeptides; Neuroprotectants; Nootropics; Peptides; Small molecules
- Mechanism of Action Apolipoprotein E agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cerebral haemorrhage; Cognition disorders; Delirium
Most Recent Events
- 28 Jul 2024 Efficacy and adverse event data from the phase II MARBLE trial in Cognition disorders and Delirium presented at the Alzheimer's Association International Conference 2024 (AAIC-2024)
- 15 Feb 2022 No development reported - Phase-II for Cerebral haemorrhage in USA (IV)
- 30 Jun 2019 AegisCN completes a phase II trial in Cerebral haemorrhage in USA (NCT03168581)